10 Best NASDAQ Growth Stocks to Buy and Hold Forever

8. iBio Inc. (NASDAQ:IBIO)

iBio Inc. (NASDAQ:IBIO) is one of the best NASDAQ growth stocks to buy and hold forever. On April 8, iBio received regulatory clearance and ethics approval to initiate its first-in-human Phase 1 clinical trial of IBIO-600 in Australia. This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and pharmacokinetics of the therapy in overweight and obese participants. The company expects to dose the first participants in Q2 2026, marking iBio’s transition into a clinical-stage biotechnology firm.

IBIO-600 is a long-acting monoclonal antibody designed to target myostatin and GDF11, which are negative regulators of muscle growth. By inhibiting these proteins, the therapy aims to preserve lean muscle mass and improve overall body composition, specifically addressing the muscle loss often associated with GLP-1 weight-loss treatments. Engineered for infrequent administration, the drug has the potential for a dosing schedule of only two to four times per year.

The advancement into clinical trials follows preclinical studies in non-human primates that showed a significant half-life of up to 52 days and increases in lean mass of up to 5.1% after a single dose. CEO Martin Brenner noted that the rapid move from program initiation to the clinic in just two years highlights the efficiency of the company’s AI-integrated discovery platform. IBIO-600 is positioned as a potentially best-in-class solution to fill critical gaps in the current obesity treatment landscape.

iBio Inc. (NASDAQ:IBIO) is a biotech company that uses its patented AI drug discovery platform and advanced computational biology to develop next-gen biopharmaceuticals. The company is focused on creating novel therapies for obesity, cardiometabolic disorders, cancer, and other hard-to-treat diseases.